-
Mashup Score: 6RP1 Combination Shows Response, Safety in Advanced Melanoma - 3 day(s) ago
Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma - 5 day(s) ago
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated #Melanoma https://t.co/hDl3h5KKpv
-
-
Mashup Score: 4Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma - 7 day(s) ago
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated #Melanoma https://t.co/hDl3h5KKpv
-
-
Mashup Score: 8Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment - 18 day(s) ago
Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative treatment in advanced melanoma, and relevant data, peer-reviewed literature, and FDA approvals in 2024. She also provides a look ahead at what is on the horizon in 2025 with regard to care for patients with advanced melanoma. In this second installment of a two-part discussion about ovarian cancer advances for The ASCO
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Don't miss this video featuring Allison Betof Warner, MD, PhD, reviewing research in the treatment of advanced #melanoma, including tumor-infiltrating lymphocyte (TIL) therapy. https://t.co/SKAoQM2tQY https://t.co/cjYwZg5bM8
-
-
Mashup Score: 1Mom Welcomes Baby After Cancerous Tumor Threatened Their Lives. Now She’s Looking Forward to Their First Christmas at Home - 22 day(s) ago
An Illinois mom is thankful as she looks forward to celebrating her first Christmas with her son — months after doctors discovered a cancerous tumor and performed an emergency cesarean section to save their lives.
Source: PEOPLE.comCategories: General Medicine News, Oncologists1Tweet-
Months after metastatic #melanoma threatened their lives, the Johnsons are celebrating their first Christmas as a family of 3! Read about their experience, and the doctors @LurieCancer & @NorthwesternMed who made it possible! https://t.co/gRhdt0AnpK via @people
-
-
Mashup Score: 4Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma - 25 day(s) ago
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated #Melanoma https://t.co/hDl3h5KKpv
-
-
Mashup Score: 8Responses to immune checkpoint inhibitor therapy in NF1 mutated cutaneous melanoma. - 1 month(s) ago
We present data on radiographic responses to ICI therapy in advanced melanoma patients with tumors harboring NF1 (Neurofibromatosis 1) mutations.
Source: focusonneurology.comCategories: General Medicine News, Oncologists1Tweet-
NF1 mutated #melanoma appears to have high rates of radiographic responses to ICI therapy. Prospective validation of this finding, particularly in patients with CNS metastasis, is warranted. https://t.co/X66FosOVlo https://t.co/wNFg7sIEgi
-
-
Mashup Score: 1
The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak or observation.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
The first patient was enrolled in a phase 3 trial and was randomly assigned to receive treatment for non-metastatic uveal #melanoma, according to a study. https://t.co/6xdDDhrTga
-
-
Mashup Score: 17Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas - 1 month(s) ago
This cohort study examines the association between the risks of melanoma-associated death and nonmelanoma-associated death for each 0.1-mm increase in Breslow thickness from 0.1 mm to 1.0 mm in a large cohort of adults diagnosed with a first invasive primary melanoma of 1.0 mm or smaller in…
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet-
#Melanoma survival rates differ significantly with tumor thickness. Patients with tumors 0.8-1.0 mm face higher mortality risk than those with thinner lesions, highlighting the need for long-term monitoring. @JAMADerm https://t.co/nmDUMZgQKC https://t.co/6bv9uelYFh
-
-
Mashup Score: 14A lipid made by tumour cells reprograms immune cells - 1 month(s) ago
Nature – Insights into how cancer cells become unresponsive to therapy.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Congratulations to @obenaufa and team for this important new study looking at crosstalk between tumor and immune cells mediated by lipids. Relevant for #melanoma but likely other cancers too. Check it out: https://t.co/oi0zg6N0X7 https://t.co/FIEhx92WKI
-
RP1 plus nivolumab led to responses and had a favorable safety profile in patients with advanced #melanoma whose disease progressed on or after prior anti-PD-1 therapy, according to data from the phase 2 IGNYTE trial. @MKWongMDPhD @MDAndersonNews https://t.co/iGIF7YdBFl